サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：免疫タンパク質診断検査の世界市場-2023年～2030年
市場調査レポート
商品コード
1345425

免疫タンパク質診断検査の世界市場-2023年～2030年

Global Immunoprotein Diagnostic Testing Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
免疫タンパク質診断検査の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

免疫タンパク質診断検査の世界市場は、2022年に94億米ドルに達し、2023-2030年の予測期間中にCAGR 6.9%で成長し、2030年には158億米ドルに達すると予測されています。

免疫タンパク質診断検査は、免疫グロブリンやプレアルブミンなどの特定のタンパク質を分析するために、体内の免疫タンパク質のレベルを検出する診断手順です。継続的な技術開発により、免疫タンパク質診断検査市場は世界的に活況を呈しています。これらの革新的技術は、製品のライフサイクルを短縮し、市場の境界を広げることで、いくつかの医療分野のビジネスチャンスを生み出しています。

心血管疾患、がん、糖尿病、呼吸器疾患などの疾患は、人口の死亡率の大半を占める原因または要因となっています。これらの慢性疾患の増加により、慢性疾患の早期診断のための免疫タンパク質検査が増加しています。これらの検査は迅速な結果を提供し、すぐに病状を治療するのに役立ちます。

さらに、技術の進歩、人口の間での慢性疾患の有病率の増加、疾患の早期診断に関する意識の高まりが、今後一定期間の市場を牽引する要因となっています。

ダイナミクス

診断検査における進歩の高まり

免疫診断検査の進歩は、関節リウマチやセリアック病などの疾患の治療において、診断の正確性と信頼性を高めます。例えば、MDPIジャーナル誌によると、2023年には、マイクロ流体技術と機械学習の組み合わせにより、迅速、高感度、選択的、正確かつ容易に複数の免疫バイオマーカーをハイスループットで検出することが可能になり、病気の早期診断に有効な免疫バイオマーカーの高度なPOC（ポイントオブケア）検出プラットフォームとして活用できるようになります。

別の報告では、Teengamらが、HBV検出用のスマートフォンベースのポータブル免疫センシングデバイスを紹介し、臨床サンプル中のHBsAgの検出限界は約0.17μg/mLでした。スマートフォンを利用することで、この低コストの電気化学免疫センサーは、高感度で携帯可能なリアルタイム結果の提供以外にも活用されています。

自己免疫疾患の増加

自己免疫疾患は約10人に1人が罹患しています。自己免疫疾患には、1型糖尿病、関節リウマチ、全身性エリテマトーデス、炎症性腸疾患などが含まれます。その負担は、個々の疾患によって速度は異なるもの、時間とともに増加し続けています。いくつかの自己免疫疾患の間で観察される社会経済的、季節的、地域的格差は、疾患の病因に環境因子が関与していることを示唆しています。

例えば、BMJジャーナルによると、2023年には自己免疫疾患は世界人口の約10％が罹患し、女性の13％、男性の7％が罹患します。2040年までに、18歳以上の米国成人の推定7,840万人（25.9％）が、医師から関節炎と診断されると予測されています（BRFSS）。ここ数十年の間に、主な小児慢性自己免疫疾患の罹患率は急速に増加しています。1型糖尿病は、世界中で年間2.4％、欧州では3～4％の罹患率の増加が推定されています。

高い診断検査費用

パンデミック後、病気の早期診断に対する需要が高まっているため、診断にかかる費用は日々高騰しています。例えば、Scientific Electronic Library Onlineによると、高齢のメディケア受給者の3分の2が2つ以上の慢性疾患を抱えています。彼らは医療費の99％を占めていますが、その理由は病院での合併症のリスクが高まり、費用が増加するためです。2022年3月から6月にかけて、6つの民間検査機関からIFATとELISAキットの価格が提供されました。消費者の1サンプルあたりの平均最終コストは、IFATで30.69米ドル、ELISAで4.88米ドルと推定されました。これらは中低所得国には高すぎて手が出ない状態です。したがって、ほとんどの人は早期診断をスキップし、手遅れになってから末期疾患の治療を受けています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 診断検査の進歩
    • 自己免疫疾患の増加
    • 抑制要因
      • 診断検査費用の高騰
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 製品タイプ別

  • 機器・キット
    • ラジオイムノアッセイ
    • 免疫濁度測定法
    • 免疫タンパク質電気泳動法
    • 酵素結合免疫吸着測定法
    • 化学発光アッセイ
    • 蛍光アッセイ
    • 比色アッセイ
    • その他
  • 試薬
  • その他

第8章 検査タイプ別

  • 免疫グロブリン診断検査
  • C反応性タンパク質（CRP）診断検査
  • 補体系蛋白診断検査
  • 遊離軽鎖診断検査
  • ハプトグロビン診断検査
  • プレアルブミン診断検査
  • その他

第9章 用途別

  • 自己免疫疾患検査
  • 感染症検査
  • 腫瘍検査
  • アレルギー検査
  • 毒物検査
  • その他

第10章 エンドユーザー別

  • 病院・クリニック
  • 診断検査室
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Abbott Laboratories
    • 企業概要
    • 製品タイプ別ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Thermo Fisher Scientific Inc
  • Bio-Rad Laboratories, Inc
  • Danaher Corporation
  • F. Hoffmann-La Roche Ag
  • Enzo Biochem, Inc
  • Siemens AG
  • Ortho Clinical Diagnostics
  • Diasorin S.P.A
  • Abcam Plc

第14章 付録

目次
Product Code: CD2306

Overview

Global Immunoprotein Diagnostic Testing Market reached US$ 9.4 billion in 2022 and is expected to reach US$ 15.8 billion by 2030 growing with a CAGR of 6.9% during the forecast period 2023-2030.

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze specific proteins such as immunoglobulin and pre-albumin. With continuous technological development, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Conditions such as cardiovascular disease, cancer, diabetes, and respiratory disease were causes or contributing factors for most of the mortality cases among the population. Due to the rise in these chronic diseases, immunoprotein testing has increased for early diagnosis of chronic diseases. These provide a rapid result, which aids in treating the condition in no time.

Furthermore, technological advancements, the increasing prevalence of chronic diseases among the population, and growing awareness about early disease diagnosis are the factors that drive the market in the forthcoming period.

Dynamics

Rising Advancements in Diagnostic Testing

Advancements in immunodiagnostic testing make the diagnosis more accurate and reliable for the treatment of diseases such as rheumatoid arthritis, celiac disease, etc. For instance, according to MDPI Journals, in 2023, the combination of microfluidic technology and machine learning effectively achieved the high-throughput detection of multiple immune biomarkers in a rapid, sensitive, selective, accurate, and easy-to-implement manner to be exploited as an advanced point-of-care (POC) detection platform for immune biomarkers effectively applicable for the early-stage diagnosis of diseases.

In another report, Teengam et al. introduced a smartphone-based portable immunosensing device for the detection of HBV, and the limit of detection was about 0.17 µg/mL of HBsAg in the clinical samples. With the use of smartphones, this low-cost electrochemical immunosensor not only provides real-time results with high sensitivity and portability

Increasing Incidence of Autoimmune Diseases

Autoimmune diseases affect about one in ten individuals. Autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Their burden continues to increase over time, albeit at varying rates across individual conditions. The socio-economic, seasonal, and regional disparities observed among several autoimmune disorders implicate environmental factors in disease pathogenesis.

For instance, according to BMJ journals, in 2023, autoimmune diseases affect around 10% of the global population, with 13% of women and 7% of men involved. By 2040, an estimated 78.4 million (25.9%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis (BRFSS). During the last decades, the incidence of the major pediatric chronic autoimmune diseases has increased rapidly1. Type 1 Diabetes has had an estimated annual increase of incidence of 2.4% per year worldwide and 3-4% in Europe.

High Costs of Diagnostic Tests

The cost of diagnosis is skyrocketing every day as the demand for early disease diagnosis has increased post-pandemic. For instance, according to Scientific Electronic Library Online states that two-thirds of older Medicare beneficiaries had two or more chronic conditions. They accounted for 99% of health expenditures, but the reason for this is a more heightened risk of hospital complications that increase the costs. Between March and June 2022, the prices of IFAT and ELISA kits were provided by six private laboratories. The average final cost per sample for consumers was estimated at US$ 30.69 for IFAT and US$ 4.88 for ELISA. These are too high for low and middle-income countries to afford; hence, most people skip early diagnosis and get treated for an end-stage disease when it's too late.

Segment Analysis

The global immunoprotein diagnostic testing is segmented based on product type, test type, application, end-user and region.

The Enzyme-linked immunosorbent assay Segment Accounted for Approximately 35.7% of the Market Share

Enzyme-linked immunosorbent assay is expected to increase the market share as the accuracy has increased. A rise in product launches due to the demand for immunodiagnostic testing is observed. For instance, in July 2022 KSL Beutner Laboratories launched a first-to-market Indirect Immunofluorescence (IIF) serum blood test in the US that positively identifies laminin 332, an antigen associated with the chronic, debilitating autoimmune disease mucous membrane pemphigoid (MMP).

Furthermore, in August 2023, Thermo Fisher Scientific launched the EXENT Solution. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. EXENT-iQ, is an intelligent and intuitive workflow software, including data review.

Geographical Analysis

North America accounted for Approximately 39.3% of the Market Share in 2022

North America is dominating the global immunoprotein diagnostic testing market and accounting for the largest market share, owing to rising incidences of chronic diseases, and rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year.

By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. Accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

COVID-19 Impact Analysis

The global pandemic has changed narratives around human health, compelling the medical research industry to develop new medical technologies and drugs. This factor reflects the pandemic's positive impact on the growth of the global immunoprotein diagnostic market. The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global immunoprotein diagnostic testing market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity

Lower capital expenditure is ongoing as businesses slow on investments, held back by inflation concerns and weaker demand. With slower growth and heightened inflation, expanded markets appear to enter a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path pose a real risk of the world experiencing more critical supply chain pain and manufacturing disruptions hindering the market.

By Product Type

  • Instruments and Kits
  • Radioimmunoassay
  • Immunoturbidity Assay
  • Immunoprotein Electrophoresis
  • Enzyme-linked immunosorbent assay
  • Chemiluminescence Assay
  • Fluorescence Assay
  • Colorimetric Assay
  • Others
  • Reagents
  • Others

By Test Type

  • Immunoglobulin Diagnostic Tests
  • C-Reactive Protein (CRP) Diagnostic Tests
  • Complement System Proteins Diagnostic Tests
  • Free Light Chain Diagnostic Tests
  • Haptoglobin Diagnostic Tests
  • Prealbumin Diagnostic Tests
  • Others

By Application

  • Autoimmune Disease Testing
  • Infectious Disease Testing
  • Oncology Testing
  • Allergy Testing
  • Toxicology Testing
  • Others

By End Users

  • Hospital and clinics
  • Diagnostic laboratories
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In July 2023, Anbio's AF-100S FIA Solution is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes. The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients
  • In May 2022, Omega Quant launched an HbA1c Test with a sample collection kit that allows for testing at home. This simple, safe, convenient test measures the amount of sugar (glucose) in the blood.
  • American Society of Tropical Medicine & Hygiene is conducting its 2023 annual meeting in Chicago, USA from October 18-22 where research Meets real-world experience. The meeting draws tropical medicine and global health professionals representing academia, foundations, government, not-for-profit organizations, non-governmental organizations, the private sector, the military, and private practice.

Competitive Landscape

The major global players in the immunoprotein diagnostic testing market include: Abbott Laboratories, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, F. Hoffmann-La Roche Ag, Enzo Biochem, Inc, Siemens AG, Ortho Clinical Diagnostics, Diasorin S.P.A, and Abcam Plc among others.

Why Purchase the Report?

  • To visualize the global immunoprotein diagnostic testing market based on product type, test type, application, end-user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of immunoprotein diagnostic testing market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global immunoprotein diagnostic testing market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by Technology
  • 3.4. Snippet by Application
  • 3.5. Snippet by End User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Advancements in Diagnostic Testing
    • 4.1.2. Increasing Incidence of Autoimmune Diseases
    • 4.1.3. Restraints
      • 4.1.3.1. High Costs of Diagnostic Tests
    • 4.1.4. Opportunity
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments and Kits
    • 7.2.1. Radioimmunoassay
    • 7.2.2. Immunoturbidity Assay
    • 7.2.3. Immunoprotein Electrophoresis
    • 7.2.4. Enzyme-linked immunosorbent assay
    • 7.2.5. Chemiluminescence Assay
    • 7.2.6. Fluorescence Assay
    • 7.2.7. Colorimetric Assay
    • 7.2.8. Others
  • 7.3. Reagents
  • 7.4. Others

8. By Test Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 8.1.2. Market Attractiveness Index, By Test Type
  • 8.2. Immunoglobulin Diagnostic Tests
  • 8.3. C-Reactive Protein (CRP) Diagnostic Test
  • 8.4. Complement System Proteins Diagnostic Test
  • 8.5. Free Light Chain Diagnostic Tests
  • 8.6. Haptoglobin Diagnostic Tests
  • 8.7. Prealbumin Diagnostic Tests
  • 8.8. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Autoimmune Disease Testing
  • 9.3. Infectious Disease Testing
  • 9.4. Oncology Testing
  • 9.5. Allergy Testing
  • 9.6. Toxicology Testing
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals and Clinics
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Diagnostic laboratories
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. UK
      • 11.3.8.3. France
      • 11.3.8.4. Italy
      • 11.3.8.5. Russia
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. Australia
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Abbott Laboratories
    • 13.1.1. Company Overview
    • 13.1.2. Product Type Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Thermo Fisher Scientific Inc
  • 13.3. Bio-Rad Laboratories, Inc
  • 13.4. Danaher Corporation
  • 13.5. F. Hoffmann-La Roche Ag
  • 13.6. Enzo Biochem, Inc
  • 13.7. Siemens AG
  • 13.8. Ortho Clinical Diagnostics
  • 13.9. Diasorin S.P.A
  • 13.10. Abcam Plc

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us